{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:38Z","timestamp":1787732378832,"version":"build-2784847793"},"reference-count":70,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-\u03b1 monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients. Numerous clinical trials are currently ongoing to test novel therapeutic targets in HS. The IL-17-mediated cascade is the target of several biologic agents that have shown efficacy and safety in treating moderate-to-severe HS. Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics15102450","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T03:07:47Z","timestamp":1697080067000},"page":"2450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa"],"prefix":"10.3390","volume":"15","author":[{"given":"Dalma","family":"Malvaso","sequence":"first","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-2336","authenticated-orcid":false,"given":"Laura","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Coscarella","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Rubegni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","article-title":"The prevalence of hidradenitis suppurativa and its potential precursor lesions","volume":"35","author":"Jemec","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Montero-Vilchez, T., Diaz-Calvillo, P., Rodriguez-Pozo, J.A., Cuenca-Barrales, C., Martinez-Lopez, A., Arias-Santiago, S., and Molina-Leyva, A. (2021). The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18136709"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/1744666X.2018.1449647","article-title":"An update on the pathogenesis of hidradenitis suppurativa: Implications for therapy","volume":"14","author":"Negus","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2020.00847","article-title":"Hidradenitis Suppurativa as a Potential Subtype of Autoinflammatory Keratinization Disease","volume":"11","author":"Nomura","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/ijd.15910","article-title":"Metabolic syndrome and hidradenitis suppurativa: Epidemiological, molecular, and therapeutic aspects","volume":"61","author":"Mintoff","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 Family of Cytokines in Health and Disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25487","DOI":"10.1074\/jbc.M111.240671","article-title":"Tumor necrosis factor alpha-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor kappaB","volume":"286","author":"Johansen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/jid.2013.313","article-title":"The pattern recognition receptor NOD2 mediates Staphylococcus aureus-induced IL-17C expression in keratinocytes","volume":"134","author":"Roth","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imr.12558","article-title":"IL-25 in allergic inflammation","volume":"278","author":"Xu","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effector cytokines in inflammation","volume":"28","author":"Ouyang","year":"2008","journal-title":"Immunity"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.4049\/jimmunol.173.5.3482","article-title":"IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways","volume":"173","author":"Kao","year":"2004","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaci.2009.12.934","article-title":"Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses","volume":"125","author":"Nograles","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Nograles, K.E., Johnson-Huang, L.M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K.M., Gulati, N., Mitsui, H., Guttman-Yassky, E., and Suarez-Farinas, M. (2014). IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090284"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/bjd.14034","article-title":"Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris","volume":"174","author":"Chiricozzi","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: Pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction","volume":"139","author":"Wolk","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.18556","article-title":"Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa","volume":"182","author":"Navrazhina","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jid.2021.02.742","article-title":"In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes","volume":"141","author":"Navrazhina","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaad.2021.07.035","article-title":"The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris","volume":"86","author":"Navrazhina","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chu, C.B., Yang, C.C., Hsueh, Y.Y., Chen, P.C., Hong, Y.K., Kuo, Y.Y., and Tsai, S.J. (2023). Aberrant expression of IL-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa. Br. J. Dermatol., ljad273.","DOI":"10.1093\/bjd\/ljad273"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jaci.2022.12.823","article-title":"Pellino-1 promotes intrinsic activation of skin-resident IL-17A-producing T cells in psoriasis","volume":"151","author":"Kim","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","article-title":"Single-cell transcriptomics suggest distinct upstream drivers of IL-17A\/F in hidradenitis versus psoriasis","volume":"152","author":"Kim","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jid.2023.03.515","article-title":"509 IL-17A and IL-17F in the pathogenesis of hidradenitis suppurativa: Insights from early and chronic lesions","volume":"143","author":"Skelton","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1189\/jlb.0405182","article-title":"Cytokines and cardiovascular disease","volume":"78","author":"Mehra","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"ref_41","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03713619?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=3&limit=10&intr=secukinumab."},{"key":"ref_42","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03713632?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=4&limit=10&intr=secukinumab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): Week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_44","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04179175?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=2&limit=10&intr=secukinumab."},{"key":"ref_45","unstructured":"(2023, July 31). Novartis Receives European Approval for Cosentyx\u00ae as First and Only IL-17A Inhibitor for Hidradenitis Suppurativa. Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/jdv.17178","article-title":"Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: Results from an Italian multicentric retrospective study in a real-life setting","volume":"35","author":"Ribero","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_49","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/search?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=2&limit=10&intr=NCT03248531."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_51","unstructured":"Kimball, A.B., Zouboulis, C.C., and Sayed, C. (2023, January 17\u201321). Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo-controlled, multicenter studies. Proceedings of the American Academy of Dermatology Annual Meeting, New Orleans, LA, USA. AAD Late-Breaking Research Program."},{"key":"ref_52","unstructured":"(2023, July 31). Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks. Available online: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/Bimekizumab-Phase-3-Data-in-Hidradenitis-Suppurativa-Show-Clinically-Meaningful-Deep-and-Maintained-Response-over-48-Weeks."},{"key":"ref_53","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03960268?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=1&limit=10&intr=brodalumab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjd.21060","article-title":"Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum","volume":"187","author":"Navrazhina","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_56","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04979520?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=2&limit=10&intr=brodalumab&page=1."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/1346-8138.15807","article-title":"Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases","volume":"48","author":"Yoshida","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ijd.14792","article-title":"Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure","volume":"59","author":"Arenbergerova","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_59","unstructured":"(2023, July 31). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02421172?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=1&limit=10&intr=CJM112%20."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"(2023). Clinical trial results for treatment of psoriasis with izokibep. Br. J. Dermatol., 189, e70.","DOI":"10.1093\/bjd\/ljad291"},{"key":"ref_62","unstructured":"(2023, July 25). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05355805?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=1&limit=10&intr=Izokibep."},{"key":"ref_63","unstructured":"ACELYRIN, Inc. (2023, July 25). Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to- Severe Hidradenitis Suppurativa. Available online: https:\/\/www.prnewswire.com\/news-releases\/acelyrin-inc-announces-izokibep-achieves-hiscr100-responses-at-12-weeks-in-moderate-to-severe-hidradenitis-suppurativa-301775533.html."},{"key":"ref_64","unstructured":"(2023, July 25). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05905783?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=2&limit=10&intr=Izokibep."},{"key":"ref_65","unstructured":"(2023, July 26). Clinicaltrial.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05322473?cond=Hidradenitis%20Suppurativa&aggFilters=phase:0%201%202%203,status:not%20rec%20com%20act&rank=1&limit=10&intr=NCT05322473."},{"key":"ref_66","unstructured":"(2023, July 26). MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody\u00ae Sonelokimab in Hidradenitis Suppurativa. Available online: https:\/\/ir.moonlaketx.com\/news-releases\/news-release-details\/moonlake-immunotherapeutics-achieves-landmark-milestone-positive."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: A multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Tsai, Y.C., Hung, C.Y., and Tsai, T.F. (2023). Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051351"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Huang, C.H., Huang, I.H., Tai, C.C., and Chi, C.C. (2022). Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061303"},{"key":"ref_70","unstructured":"(2023, September 30). US Food and Drug Administration Kineret, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103950s5136lbl.pdf."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/10\/2450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:05:06Z","timestamp":1760130306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/10\/2450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":70,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["pharmaceutics15102450"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15102450","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}